A specifier sourcing PVC compound for two product lines — an EU automotive aftermarket harness and a US electronics OEM channel — cannot use the same DOP date for both, and the gap is widening. The phase-out of DOP is real, but it does not arrive as a single date on a calendar. It arrives in tiers, by jurisdiction and by application, and it almost always shows up in a major OEM’s purchase-order language before it shows up in a statute.
The regulatory landscape is shifting toward a position where the statute is a downstream confirmation of an OEM-spec decision that already happened — sometimes months ago, sometimes decades ago, depending on the sector.
Why “When Does the EU Ban DOP?” Is the Wrong Question
DOP is not banned globally on a single date, and treating the EU sunset like a master switch is the fastest way to build the wrong substitution sequence. The molecule itself — DOP, also written DEHP — is one substance, but REACH and the parallel regimes stack restrictions by application, with different timing for each one.
The vocabulary itself encodes the difference. “Restricted” under REACH Annex XVII means a 0.1% threshold in articles for a defined product class — toys and childcare articles for DEHP, BBP, DBP, and DIBP. “Authorisation-required” under Annex XIV means the substance is permitted only with an ECHA permit; for DEHP medical devices the original sunset of May 27, 2025 was pushed by Commission Regulation 2023/2482 to July 1, 2030.
“Prohibited” sits at the strictest end — toys above 0.1%, EEE under RoHS Recast Annex II since July 22, 2019. And then there is the category with no statute at all: “OEM-spec restricted,” where a brand owner has written the molecule out of its purchase orders ahead of any regulator.
A procurement question that lumps these four together is overconfident for a non-toy industrial sealant in the EU (still legal), and underconfident for a medical-device line selling into Kaiser Permanente or B. Braun networks in the US (already restricted by buyer spec, despite the 2030 statute date). The only useful starting question names both the jurisdiction and the application.
The Region-by-Application Phase-Out Map
The actual phase-out resolves on a grid, not a timeline. Here is the picture as of April 2026:
| Application | EU | US (federal + state) | China | India |
|---|---|---|---|---|
| Toys / childcare | Prohibited >0.1% (2005) | CPSIA 0.1% (2008) | GB 0.1% | Out of scope |
| Medical devices | Auth-required, sunset July 1, 2030 | CA AB 2300: bags 2030, tubing 2035 | None | None |
| Electrical / electronic | RoHS 0.1%, July 22, 2019 | State-level only | China RoHS, Jan 1, 2026 | None |
| Food contact | EU 10/2011, June 14, 2023 | FDA: not banned | GB restrictions | FSSAI 1.5 mg/kg, Aug 30, 2022 |
| General industrial | Permitted (Annex XVII for articles) | Permitted federally | Permitted | Permitted |
The “is DEHP banned in the US?” question that surfaces in nearly every procurement Q&A has no general answer. Federally, DEHP remains legal in most industrial applications, with the TSCA risk evaluation updated as recently as January 2026. But California’s Toxic Free Medical Devices Act tells a very different story for any IV bag sold in the state after 2030.
The cross-jurisdiction RoHS gap is the cleanest illustration of why the grid exists: same molecule, same 0.1% threshold, same EEE class, separated by 6.5 years between EU enforcement (2019) and Chinese enforcement (2026). For a multinational supply chain, that 6.5-year window has been a compliance-shifted zone all along, with specs propagating from EU buyers into Chinese suppliers via PO language, not via Chinese statute.
This duty can also be addressed by the substitution side of the grid — the receiving plasticizer is usually DOTP (DEHT), DINCH, an adipate such as DOA, or an epoxidized soybean oil (ESO) co-stabilizer — but the substitution decision belongs in a comparison framework that treats phthalate vs non-phthalate routes by application and jurisdiction. The grid above tells you when, not what to switch to.
When OEM Specs Phase Out DOP Ahead of the Statute
Once a major OEM set the spec, the entire supply chain followed. The 12-to-24-month figure quoted in trade press is true in exactly one corner of this picture, and badly wrong in the rest. OEM-vs-statute lead time runs in three distinct tiers.
Toys: a 6-to-9-year lead
Mattel and Hasbro lobbied against the EU’s 1999 emergency ban on phthalates in PVC toys for under-3s, lost, and announced worldwide phthalate removal from their young-children’s product lines that same year. The EU made the ban permanent in 2005 — six years after the OEM move — and the US CPSIA caught up in 2008. Two firms with concentrated retail share rewrote the supply chain a decade before US statute.
Medical: a 10-to-40-year lead
Kaiser Permanente switched its IV systems to DEHP-free in 2012, as Stephanie Pitts, Senior Director of Healthcare Strategy and Innovation at B. Braun, has put it, “putting them way ahead of everyone else.” California’s AB 2300, which phases DEHP and PVC out of IV bags by 2030 and IV tubing by 2035, was signed in 2024 — twelve years after Kaiser’s purchasing decision, with the IV-bag enforcement running 18 years behind it.
B. Braun has run DEHP-free across four decades. The 18-year lead is the single fact that most cleanly disproves the “12-24 month” framing for any sector where brand specs concentrate.
Electronics: a 5-to-7-year cross-jurisdiction gap
EU RoHS Recast Annex II took effect July 22, 2019; China RoHS Amendment 1 to GB/T 26572 took effect January 1, 2026 — a 6.5-year window during which multinational OEMs sourcing EEE components from Chinese suppliers had already specified the EU’s 0.1% threshold in their PO language. For any supplier facing this kind of cross-jurisdiction stack, the practical move is to plan the DEHP-out formulation work against OEM PO terms first and the local statute second.
In concentrated-brand sectors, the binding date is the OEM specification — and it arrives first by years, not months.
Where the Statute Slips and DEHP Production Continues
Statutes are not always behind. There are real cases where the statute moves, the OEM does not, and the regulator effectively retreats.
When the Regulator Retreats
Commission Regulation 2023/2482, published November 13, 2023, delayed the DEHP medical device sunset from May 27, 2025 to July 1, 2030, and the application date from November 27, 2023 to January 1, 2029, citing the need to “avoid any major disruption in the supply of medical devices.” That is a five-year statute-side slip with no OEM-side slip — Kaiser, B. Braun, and the Premier-aligned hospital networks were already DEHP-free or transitioning years before the original 2025 deadline. The procurement-binding date for the buyers that matter had already passed.
Counter-pressure runs through the toxicology side too. EFSA’s February 2019 group reassessment concluded that phthalate exposure ran “at least 20 times below the level that is safe,” a position that argues for slowing the regulatory tightening, not accelerating it.
Where Production Keeps Running
India’s FSSAI did not adopt a DEHP migration limit (1.5 mg/kg in food packaging) until August 30, 2022 — over a decade behind EU 10/2011 — and India still has no analogue to REACH Annex XIV or RoHS Annex II. DEHP and DOP keep being produced at industrial volumes in both India and China for non-restricted applications, then exported into markets without equivalent rules.
As Marco Monti and colleagues at the University of Modena wrote in the European Journal of Public Health in 2022, “substantial differences in international legislation” persist despite “essential agreement on toys and childcare articles.” In jurisdictions where the statute is loose or absent, the multinational OEM PO term has been doing the work the statute is not — propagating EU and US-market spec into Asian supply chains ahead of any local rule.
The 2023/2482 delay is the cleanest confirmation that the procurement-binding date is the OEM-spec date, regardless of which way the statute moves.
How to Sequence Your DOP Phase-Out Substitution
The procurement-binding date for DOP almost never matches the statute date — read it off the OEM spec or PO term first, and treat the regulator’s calendar as a confirmation, not the trigger. For a product line in toys or any concentrated-brand sector, assume the spec moved years ago and the only question is whether your formulation has caught up.
For a medical line, the 2030 EU sunset is the latest possible binding date, not the earliest; the actual binding date is whichever DEHP-free hospital network sits on your customer list. For EEE crossing the China-EU border, the 6.5-year RoHS gap between 2019 and 2026 has already collapsed for any supplier whose buyers are EU OEMs — the China statute is closing a gap that buyer specs closed in 2019.
The molecule has not gone away — production continues in regions without equivalent rules — but the markets that will accept it are shrinking on a schedule the regulators are publishing late.